The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy

[11] Ramiro S(2016)Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial Ann Rheum Dis 75 1081-1091

[12] Smolen J(2014)Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study Ann Rheum Dis 73 803-809

[13] van der Heijde D(2013)Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial Lancet. 381 1541-1550

[14] Singh JA(2010)Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann Rheum Dis 69 88-96

[15] Saag KG(2005)The CORRONA database Ann Rheum Dis 64 iv37-iv41

[16] Bridges SL(2005)The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis Clin Exp Rheumatol 23 S100-S108

[17] Akl EA(1983)Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire Arthritis Rheum 26 1346-1353

[18] Bannuru RR(2012)A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry Ann Rheum Dis 71 1134-1142

[19] Sullivan MC(2015)Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study Ann Rheum Dis 74 979-984

[20] Smolen JS(2014)Dynamic treatment regimes Annu Rev Stat Appl 1 447-464

[11] Ramiro S(2016)Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial Ann Rheum Dis 75 1081-1091

[12] Smolen J(2014)Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study Ann Rheum Dis 73 803-809

[13] van der Heijde D(2013)Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial Lancet. 381 1541-1550

[14] Singh JA(2010)Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann Rheum Dis 69 88-96

[15] Saag KG(2005)The CORRONA database Ann Rheum Dis 64 iv37-iv41

[16] Bridges SL(2005)The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis Clin Exp Rheumatol 23 S100-S108

[17] Akl EA(1983)Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire Arthritis Rheum 26 1346-1353

[18] Bannuru RR(2012)A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry Ann Rheum Dis 71 1134-1142

[19] Sullivan MC(2015)Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study Ann Rheum Dis 74 979-984

[20] Smolen JS(2014)Dynamic treatment regimes Annu Rev Stat Appl 1 447-464